Leptospirosis
23
4
5
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.3%
1 terminated out of 23 trials
88.9%
+2.3% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (23)
Leptospirosis Care Bundle Study
N-Acetylcysteine in Patients With Leptospirosis
Assessment of the Risk of Zoonotic Infections in Prisons in French Guiana
Cohort of Hospitalized Patients Suspected of Leptospirosis
Chronic Post-leptospirosis Manifestations in Reunion
Ex Vivo Study of Leukocyte Responses in the Blood of Patients With Leptospirosis and ex Vivo Testing of a New Host-targeted Therapeutic Strategy to Restore Phagocytosis of Leptospira
Preventive Strategies for Early and Late Complications of Leptospirosis
Xpert® Tropical Fever Test on GeneXpert® Edge X System
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Leptospirosis Registry - LeptoScope
Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO
Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia
Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Severe Leptospirosis in Non-tropical Areas
Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine
French West Indies Leptospirosis Study
The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands